What does tirzepatide cost? The price changes as your dose goes up

The number depends on your dose

Most drug prices are one number. Tirzepatide isn't, and that catches people out when they budget.

Here's what we recorded for Zepbound on the manufacturer self-pay route, observed 13 July 2026:

All three need a valid on-label prescription and programme eligibility. Taxes and fees sit on top.

A $150 gap separates the bottom tier from the top. Same drug, same supply period, same channel.

Why the tiering matters more than it looks

People typically don't stay on a starting dose.

Doses are commonly stepped up over time under clinical supervision, which means the tier you begin in is often not the tier you end up in. Budget from $299 and your later months can run $100 to $150 higher.

None of that is hidden. It's just easy to miss when you're comparing one advertised figure against another advertised figure.

We record the condition next to every price for exactly this reason. A number without its terms isn't information, and pricing presented so the eventual cost is obscured is the kind of claim advertising regulators pay attention to.³

The comparison that flips

Now put it beside semaglutide, because this is where it gets genuinely useful.

Wegovy's published self-pay price was flat at $349 per 28-day supply after its introductory period. Zepbound is tiered.

Both observed 13 July 2026. Wegovy's figure is the standard price after its two-fill introductory offer; see what semaglutide costs.

Which drug is cheaper isn't a fixed answer. It inverts depending on where you land.

Almost every GLP-1 cost comparison you'll read picks one number for each and declares a winner. On these two published programmes, that isn't a question with a single answer.

And neither figure settles anything clinical. Which compound suits a given person turns on things a price table can't see, which we go through in semaglutide vs tirzepatide.

The research-vendor number

In our price market, as of the 25 July 2026 check, tirzepatide is listed by 2 vendors at $34.00 to $180.00 per package.

Two vendors, eleven offers. That's a thin market for one of the most-discussed drugs in the world, and the thinness is the story rather than a footnote.

Those aren't monthly costs. They're package prices for material not authorized for human use, so setting $34 against $299 compares a package of unstated quantity to a stated 28-day supply of an approved product.¹

A compounded category sits between the two as well, prepared by a pharmacy rather than approved as a finished product, with its own rules and its own price band.²

One wrinkle from our lab data

Worth knowing if you're doing cost-per-milligram maths on the research market.

Across our 33 published lab records for tirzepatide, 31 vials measured over their labelled dose, at a median of +13.1%.

So a vial sold as 30mg has often held closer to 34mg. On paper that pushes your real cost per milligram below the sticker.

Don't read that as a discount. It means the label isn't a reliable statement of contents, and a number you can't rely on makes a poor basis for a calculation. Full picture in what tirzepatide is.

What to actually do with these numbers

Budget from the tier you expect to reach, not the one you start in.

Compare programmes at the same dose, since the ranking changes across tiers.

Treat every figure here as dated. The prescription snapshots were read 13 July 2026 and the vendor listings 25 July 2026. Programmes and eligibility move faster than articles do.

Use price to spot outliers, never quality. Nothing in this market makes an expensive vial a better one.

The framework behind all of that sits in why weight-care pricing resists honest comparison.